4//SEC Filing
Yen Yun 4
Accession 0001493152-20-022975
CIK 0001335105other
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 4:55 PM ET
Size
10.9 KB
Accession
0001493152-20-022975
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Purchase
Warrants to Purchase Common Stock
2020-11-30$4.75/sh+52,632$250,002→ 52,632 total(indirect: By Sino-American Cancer FDD)Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (52,632 underlying) - Purchase
Common Stock
2020-11-30$4.75/sh+52,632$250,002→ 52,632 total(indirect: By Sino-American Cancer FDD)
Holdings
- 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying) - 16,666
Options to Purchase Common Stock
Exercise: $1.68From: 2018-08-04Exp: 2023-08-04→ Common (16,666 underlying) - 16,667
Options to Purchase Common Stock
Exercise: $1.68From: 2019-08-04Exp: 2024-08-04→ Common (16,667 underlying)
Footnotes (1)
- [F1]The reporting person acquired 52,632 Units, each Unit consisting of one share of Common Stock and a five year warrant at an exercise price of $5.70 per share. The purchase price for a Unit was $4.75 per Unit.
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001684584
Filing Metadata
- Form type
- 4
- Filed
- Dec 3, 7:00 PM ET
- Accepted
- Dec 4, 4:55 PM ET
- Size
- 10.9 KB